, /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: ) ("NW Bio"), a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, reported positive results of voting at the Annual Shareholders Meeting on , 2024. There was an exceptionally strong vote turnout at the 2023 Annual Meeting, with 961.7 million votes cast out of the total 1.
2 billion shares outstanding as of the record date, comprising over 77% of all common and preferred shares outstanding. This vote turnout repeated the exceptional turnout at the 2022 Annual Meeting, where 841 million votes were cast comprising 78% of the total shares that were then outstanding. There were 5 Proposals for shareholders to decide at the 2023 Annual Meeting, and all of them were approved by shareholders with overwhelming margins.
The votes were as follows: Proposal 1: Re-Election of Class I Directors for a new 3-year term Proposal 2: Ratification of Appointment of Independent Auditor – Proposal 3: Ratification of Stock Options awarded to Management in 2020. Proposal 4: Ratification of Stock Options Awarded to Non-Executive Directors in 2020. Proposal 5: Approval, on an advisory basis, of executive compensation in 2023.
During the Annual Meeting, the Company also conducted an informal discussion session that was publicly available by audio link to all interested parties. An audio recording has also been posted on the Company's website and will remain available there through , 2024. During the discussi.
